Company Overview and News

 
GenMark Diagnostics Schedules First Quarter Financial Results Conference Call for May 1, 2018

2018-04-17 globenewswire
CARLSBAD, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 1, 2018. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc.
Upvote Downvote

 
GNMK / GenMark Diagnostics, Inc. DEFA14A

2018-04-13 sec.gov
Document UNITED STATES
Upvote Downvote

 
GNMK / GenMark Diagnostics, Inc. DEF 14A

2018-04-13 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
Snap Is Going Nowhere - Cramer's Lightning Round (4/9/18)

2018-04-10 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, April 9.
Upvote Downvote

 
GNMK / GenMark Diagnostics, Inc. / Casdin Capital, LLC - null (Activist Investment)

2018-03-27 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
Upvote Downvote

 
GNMK / GenMark Diagnostics, Inc. / Casdin Capital, LLC - null (Activist Investment)

2018-03-27 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
Upvote Downvote

 
GNMK / GenMark Diagnostics, Inc. null

2018-03-27 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Y(# @;V)J#3P\+TQI;F5A DD7M
Upvote Downvote

 
Week 12 Breakout Forecast: Short-Term Picks To Give You An Edge

2018-03-18 seekingalpha
Publishing two of the 8 new Week 12 breakout stocks that are available only to subscribers with better than 10% short-term upside potential.
Upvote Downvote

 
Yet Again, Investors Have To Readjust Expectations For GenMark

2018-03-02 seekingalpha
Although fourth-quarter results weren't bad, guidance for 2018 system placements and gross margins was well below expectation, calling into question just how much demand there is for ePlex.
Upvote Downvote

 
GNMK / GenMark Diagnostics, Inc. S-8

2018-03-01 sec.gov
Document As filed with the Securities and Exchange Commission on March 1, 2018
Upvote Downvote

 
 
GenMark Diagnostics' (GNMK) CEO Hany Massarany on Q4 2017 Results - Earnings Call Transcript

2018-02-28 seekingalpha
Good afternoon, ladies and gentlemen, and welcome to today's conference call to discuss GenMark Diagnostics' Fourth Quarter 2017 Financial Results. My name is Joey and I will be your operator on this call. After the presentation, we will conduct a question-and-answer session. Instructions will be provided at that time. [Operator Instructions] Please note that this call is being recorded today, Tuesday, February 27, 2018 at 1.
Upvote Downvote

 
GNMK / GenMark Diagnostics, Inc. 10-K (Annual Report)

2018-02-27 sec.gov
Document Table of Contents
Upvote Downvote

 
GNMK / GenMark Diagnostics, Inc. 8-K (Current Report)

2018-02-27 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2018 GENMARK DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number: 001-34753 Delaware 27-2053069 (State or other jurisdiction of incorporation) (I.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

CUSIP: 372309104